Progress in the application of Bruton's tyrosine kinase inhibitors for non-hematologic-al tumors
10.12354/j.issn.1000-8179.2025.20250447
- VernacularTitle:布鲁顿酪氨酸激酶抑制剂在非血液肿瘤中的应用进展
- Author:
Deng SHENGMING
1
;
Kong FANCONG
1
;
Li FEI
1
Author Information
1. 南昌大学第一附属医院血液科,江西省血液病临床医学研究中心,江西省血液系统疾病重点实验室(南昌市 330006)
- Publication Type:Journal Article
- Keywords:
Bruton's tyrosine kinase(BTK);
non-hematologic tumors;
application progress
- From:
Chinese Journal of Clinical Oncology
2025;52(11):588-592
- CountryChina
- Language:Chinese
-
Abstract:
Bruton's tyrosine kinase inhibitors(BTKi)are a class of drugs approved for treating patients with B cell-related hematologic malig-nancies.They function by blocking B cell signaling,thereby affecting the development and proliferation of B cell-related tumors.Research has revealed that Bruton's tyrosine kinase(BTK)is also expressed in other cells,including mast cells,dendritic cells,granulocytes,platelets,and macrophages.Furthermore,BTK's downstream signaling pathways,such as the activation of phospholipase C gamma 2(PLCγ2),Fc re-ceptor signaling path ways,and Toll-like receptor signaling pathways,are associated with various diseases.These mechanisms provide a the-oretical foundation for using BTK in treating diseases other than B cell-related tumors.This article reviews the progress in the application of BTK for non-B-cell malignancies.
